The role of neoantigen in immune checkpoint blockade therapy
Abstract Immune checkpoint inhibitor induces tumor rejection by activated host immune system. The anti-tumor immune response consists of capture, presentation, recognition of neoantigen, as well as subsequent killing of tumor cell. Due to the interdependence among this series of stepwise events, neo...
Main Authors: | Ming Yi, Shuang Qin, Weiheng Zhao, Shengnan Yu, Qian Chu, Kongming Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-11-01
|
Series: | Experimental Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40164-018-0120-y |
Similar Items
-
Prospects for combining immune checkpoint blockade with PARP inhibition
by: Anping Li, et al.
Published: (2019-09-01) -
Gut microbiome modulates efficacy of immune checkpoint inhibitors
by: Ming Yi, et al.
Published: (2018-03-01) -
A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control
by: Elena Tondini, et al.
Published: (2019-11-01) -
Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma
by: Chen, X., et al.
Published: (2022) -
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
by: Ming Yi, et al.
Published: (2019-03-01)